During the 1st quarter of 2015, the total deal value in the healthcare industry walked through the ceiling of USD 90 billion… Patent expiries looming on the horizon were one of the main rationale behind this M&A fever.
Some of the Q1 2015 biggest deals:
- AbbVie & Pharmacyclics – USD 21 billion
- Pfizer & Hospira – USD 16.8 billion
- Valean & Salix Pharmaceuticals – USD 15.8 billion
- UnitedHealth & Catamaran – USD 12.8 billion
Securing valuable and strategic assets seemed crucial in these last moves. But the prices paid were quite high.